-
AI's hunger for power sparks US private gas plant boom
-
Farage vs Count Binface: What to know about UK snap poll
-
Memphis AI data center fuels pollution fight in Black neighborhood
-
Torment of Afghan fathers as daughters deprived of education
-
Ceuta leader wants migrant detention centre after influx
-
Return of displaced Syrian Kurds to hometown suspended after violence
-
Colombia scrambles to find survivors as quake kills 111
-
Swiatek races past Shnaider into Toronto semi-finals
-
Rain postponements wreck Montreal Masters schedule
-
Meta pushes global AI vision amid race with OpenAI, Anthropic and China
-
Notts Forest owner Marinakis sues Palace over gun banner - reports
-
US judge ends graft case against India's Adani
-
Koech gets three-year ban, stripped of US 1,500m title
-
Anderson retires after 10 MLB seasons after 'too much pain'
-
Sensational Ingebrigtsen back with more European gold
-
Colombia in state of emergency as quake kills 111
-
'A scare': Brazil player leaps into tunnel in joy over goal
-
Britain's Amy Hunt wins European women's 100m gold
-
USA Swimming CFO Hilliard arrested for alleged theft
-
Trump order pushes for overhaul of childhood vaccine schedule
-
Trump insists Netanyahu relationship 'very good' despite Gaza rift
-
Global stocks mixed while oil prices jump on Hormuz
-
Ingebrigtsen delivers masterclass for seventh European athletics gold
-
Turkey MPs back historic law on reintegrating Kurdish militants
-
Colombia declares state of emergency after quake kills 111
-
'Dreams disappear' as Gaza students await evacuation to Italy
-
Golden relay double for Britain at Europeans as Marchand takes silver
-
Third European gold for Schilder in women's shot put
-
Barcelona's Araujo heads to Liverpool on loan
-
Golden relay double for Britain at Europeans as Marchand settles for silver
-
Tupac Shakur murder trial begins 30 years after rapper's death
-
US had hottest month on record in July
-
Russia bars only anti-war party from elections
-
Colombia quake leaves 69 dead, with more trapped under rubble
-
Boeing to divest tech ventures for stake in air-taxi startup
-
Bookmap Announces Partnership with Plus500 to Expand Futures Trading Access
-
Major quake rocks Colombia and neighbors, 18 confirmed dead
-
Barcelona turn down PSG offer for Torres
-
Brazil aircraft maker Embraer raises outlook after record revenue
-
Buildings collapse as major quake rocks Colombia and neighbors
-
Drought forces water restrictions across nearly 70 percent of France
-
Meta releases new AI model as Zuckerberg lays out vision
-
Europe wary as gas stocks languish at lows while winter looms
-
OFunded Enters the Prop Trading Market With Broker-Backed Infrastructure From OFinancial Markets
-
Freedom Holding Corp. Reports 40% Increase in Quarterly Revenue to $732.5 Million
-
What next for beleaguered FIFA president Infantino?
-
Stocks mostly flat with focus on US inflation
-
Greece contains new wind-driven fire near Athens
-
UK radio broke rules in announcing king's death: watchdog
-
Massive shake-up of Hungary media after Orban's exit
Study on serotonin and depression sparks fierce debate
A controversy in the scientific community over a recent claims anti-depressants can be ineffective at treating depression has highlighted the difficulties in understanding mental health conditions.
One of the prevailing theories currently focuses on serotonin. Depression has been linked to a lack of the molecule, which is involved in transmitting emotions to the brain.
Claims that depression has no link to a chemical imbalance in the brain related to serotonin, casting doubt on the need for anti-depressants, have sparked fierce reaction.
A study by psychiatrists Joanna Moncrieff and Mark Horowitz in the journal Molecular Psychiatry in July concluded that there was no proven link between a lack of serotonin and depression.
The authors said it queried the underlying assumption behind the use of anti-depressants, which are mostly developed to alter serotonin levels, undoing a theory that for decades acted as a framework for research.
The study is based on several previous publications, but it quickly attracted criticism -- particularly its presentation by Moncrieff, known for her scepticism towards biological explanations of depression and her radical stance against the pharmaceutical industry.
"I'm broadly in agreement with the authors' conclusions about our current efforts, though I lack their adamantine certainty," psychiatrist Phil Cowen said on the Science Media Centre website.
"No mental health professional" would endorse the view that a complex condition like depression "stems from a deficiency in a single neurotransmitter", Cowen added.
- 'Mainstream' psychiatry -
Some peers have questioned the methodology, which measured an indirect trace of serotonin rather than taking direct measurements of the molecule.
Moncrieff, who wants to break with what she calls "mainstream" psychiatry, believes the serotonin theory still occupies an important, albeit less prominent, place in the profession.
"Even if leading psychiatrists were beginning to doubt the evidence for depression being related to low serotonin, no one told the public," the British psychiatrist wrote on her blog.
The connection between depression and serotonin is firmly rooted in the popular imagination. French author Michel Houellebecq gave the title "Serotonin" to his 2019 novel in which the main character is depressed.
Moncrieff's undermining of the serotonin theory to argue against current anti-depressants, going beyond the conclusions of her own study, has sparked the most vehement criticism.
Swiss psychiatrist Michel Hofmann told AFP her study was "serious" and contributed to expert debates about depression.
"But I don't think it is an article that should have any impact in the short term on the prescription of anti-depressants," he said.
Moncrieff has warned that anti-depressant treatment should not be suddenly interrupted. But for her, the benefits of a course of anti-depressants are doubtful if it is based on a discredited theory.
But many stress that the effectiveness of the treatments has been scientifically assessed, irrespective of the primary cause of depression.
The medicines used to treat depression "are usually many and ultimately, in most cases, we don't know what exactly makes a treatment effective", Hofmann added.
Debates on the role of serotonin only illustrate how difficult it is to understand the biological and social workings of an illness as complex as depression.
The challenges are forcing researchers to move away from models that are incomplete by their very nature.
"We are still at theories and we continue to search and test models against each other," Hofmann said.
G.Schulte--BTB